Methadone Anesthesia For Kidney Transplant Receptors

Sponsor
University of Sao Paulo General Hospital (Other)
Overall Status
Recruiting
CT.gov ID
NCT04908345
Collaborator
(none)
32
1
2
7.5
4.3

Study Details

Study Description

Brief Summary

Intraoperative methadone or fentanyl will be administered to patients submitted to kidney transplant surgery. Postoperative pain, analgesic consumption and side effects will be evaluated

Condition or Disease Intervention/Treatment Phase
Phase 3

Detailed Description

Despite recent developments in postoperative pain control, many patients still experience moderate or severe pain after surgery. It is estimated that severe postoperative pain occurs in 20 to 40% of surgical procedures. With the development of kidney transplant services, a better study of the intraoperative analgesia used in this procedure and its impact on the postoperative is necessary. The management of postoperative pain in renal transplant recipients is essential to improve the quality of postoperative care, and may even impact the prognosis of the renal graft. One of the strategies to improve pain control in the perioperative period is the intraoperative use of intravenous methadone, given its pharmacokinetic profile. Methadone is an opioid agonist of µ receptors, it is also a Glutamate antagonist by blocking the N-methyl-D-aspartate (NMDA) receptor, and inhibits the reuptake of serotonin and norepinephrine. When administered in doses of 20 to 30mg, the analgesia generated by methadone can last from 24 to 36 hours. There is also evidence that the use of methadone in doses of 0.2 to 0.3 mg / kg is not associated with a higher incidence of side effects when compared to other opioids with short or intermediate duration of action, such as fentanyl, sufentanil and morphine. The aim of this study is to evaluate the effectiveness of using intraoperative methadone to reduce postoperative pain in patients undergoing kidney transplant surgery (recipients). Patients will be submitted to standardized general anesthesia, and the opioid used in anesthetic induction will be methadone or fentanyl with additional boluses if necessary. After extubation, Fentanyl will be installed in an intravenous analgesia pump controlled by the patient. Differences between groups regarding opioid consumption, pain scores, side effects and patient satisfaction will be assessed

Study Design

Study Type:
Interventional
Anticipated Enrollment :
32 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Intervention Model Description:
Methadone x FentanylMethadone x Fentanyl
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Intraoperative Use Of Methadone In The Prevention of Postoperative Pain in Kidney Transplant Receptors
Actual Study Start Date :
May 17, 2021
Anticipated Primary Completion Date :
Jan 1, 2022
Anticipated Study Completion Date :
Jan 1, 2022

Arms and Interventions

Arm Intervention/Treatment
Experimental: Methadone

Methadone 0,075mg/kg for induction and half of induction dose of boluses as needed during surgery

Drug: Methadone
Used at induction and during surgery

Active Comparator: Fentanyl

Fentanyl 3 mcg/kg for induction and half of induction dose of boluses as needed during surgery

Drug: Fentanyl
Used at induction and during surgery

Outcome Measures

Primary Outcome Measures

  1. Pain score 24h postoperatively [One day after surgery]

    Reported pain in a scale of 0 (no pain) to 10 (maximum pain)

  2. Pain score 48h postoperatively [Two days after surgery]

    Reported pain in a scale of 0 (no pain) to 10 (maximum pain)

  3. Pain score 72h postoperatively [Three days after surgery]

    Reported pain in a scale of 0 (no pain) to 10 (maximum pain)

  4. Analgesic use 24h postoperatively [One day after surgery]

    Analgesic use after surgery

  5. Analgesic use 48h postoperatively [Two days after surgery]

    Analgesic use after surgery

  6. Analgesic use 72h postoperatively [Three days after surgery]

    Analgesic use after surgery

Secondary Outcome Measures

  1. Opioid-related side effects 24h postoperatively [One day after surgery]

    Opioid-related side effects

  2. Opioid-related side effects 48h postoperatively [Two days after surgery]

    Opioid-related side effects

  3. Opioid-related side effects 72h postoperatively [Three days after surgery]

    Opioid-related side effects

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patients over 18 years of age

  • With indication for kidney transplant surgery

  • Who sign the informed consent form

Exclusion Criteria:
  • Patients who refuse to participate in the study

  • Known allergy to any drug used in this protocol

  • Presence of stage III or IV congestive heart failure

  • Increase in QT interval on electrocardiogram (QT> 500 msec)

  • Preemptive kidney transplantation (defined by transplantation in a patient who has not yet started kidney replacement therapy).

Contacts and Locations

Locations

Site City State Country Postal Code
1 Hospital das Clínicas da FMUSP Sao Paulo SP Brazil 05403-000

Sponsors and Collaborators

  • University of Sao Paulo General Hospital

Investigators

  • Principal Investigator: Felipe C Machado, MD, PhD, USP

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Felipe Chiodini Machado, Principal Investigator, University of Sao Paulo General Hospital
ClinicalTrials.gov Identifier:
NCT04908345
Other Study ID Numbers:
  • MEFERENAL
First Posted:
Jun 1, 2021
Last Update Posted:
Jun 1, 2021
Last Verified:
May 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 1, 2021